[1] Cephalalgia Group. Guidelines for diagnosis and treatment of migraine in China[J]. Zhongguo Teng Tong Yi Xue Za Zhi, 2011, 17:65-86.[头面痛学组.中国偏头痛诊断 治疗指南[J].中国疼痛医学杂志, 2011, 17:65-86.]
[2] Olesen J. International classification of headache disorders[J]. Lancet Neurol, 2018, 17:396-397.
[3] Katsarava Z, Mania M, Lampl C, Herberhold J, Steiner TJ. Poor medical care for people with migraine in Europe-evidence from the Eurolight study[J]. J Headache Pain, 2018, 19:10.
[4] Headache Classification Committee of the International Headache Society (IHS). The international classification of headache disorders, 3rd edition[J]. Cephalalgia, 2018, 38:1-211.
[5] Farzianpour F, Rahimi Foroushani A, Shahidi Sadeghi N, Ansari Nosrati S. Relationship between ‘patient's rights charter’ and patients' satisfaction in gynecological hospitals[J]. BMC Health Serv Res, 2016, 16:476.
[6] Lee MJ, Park BY, Cho S, Park H, Chung CS. Cerebrovascular reactivity as a determinant of deep white matter hyperintensities in migraine[J]. Neurology, 2019, 92:e342-350.
[7] Daghlas I, Rist PM, Chasman DI. Effect of genetic liability to migraine on cognition and brain volume:a Mendelian randomization study[J]. Cephalalgia, 2020, 40:998-1002.
[8] Gil-Gouveia R, Martins IP. Cognition and cognitive impairment in migraine[J]. Curr Pain Headache Rep, 2019, 23:84.
[9] Dem?r ÜF, Bozkurt O. Effects of perceived social support, depression and anxiety levels on migraine[J]. Noro Psikiyatr Ars, 2020, 57:210-215.
[10] Pearl TA, Dumkrieger G, Chong CD, Dodick DW, Schwedt TJ. Impact of depression and anxiety symptoms on patient-reported outcomes in patients with migraine:results from the American registry for migraine research (ARMR)[J]. Headache, 2020, 60:1910-1919.
[11] West BH, Noureddin N, Mamzhi Y, Low CG, Coluzzi AC, Shih EJ, Gevorgyan Fleming R, Saver JL, Liebeskind DS, Charles A, Tobis JM. Frequency of patent foramen ovale and migraine in patients with cryptogenic stroke[J]. Stroke, 2018, 49:1123-1128.
[12] Otlivanchik O, Liberman AL. Migraine as a stroke mimic and as a stroke chameleon[J]. Curr Pain Headache Rep, 2019, 23:63.
[13] Ning M, Lo EH, Ning PC, Xu SY, McMullin D, Demirjian Z, Inglessis I, Dec GW, Palacios I, Buonanno FS. The brain's heart-therapeutic opportunities for patent foramen ovale (PFO) and neurovascular disease[J]. Pharmacol Ther, 2013, 139:111-123.
[14] Teshome MK, Najib K, Nwagbara CC, Akinseye OA, Ibebuogu UN. Patent foramen ovale:a comprehensive review[J]. Curr Probl Cardiol, 2020, 45:100392.
[15] Singh HS, Katchi F, Naidu SS. PFO closure for cryptogenic stroke:a review and clinical treatment algorithm[J]. Cardiol Rev, 2017, 25:147-157.
[16] Mahmoud AN, Elgendy IY, Agarwal N, Tobis JM, Mojadidi MK. Identification and quantification of patent foramen ovale-mediated shunts:echocardiography and transcranial doppler[J]. Interv Cardiol Clin, 2017, 6:495-504.
[17] Del Sette M, Angeli S, Leandri M, Ferriero G, Bruzzone GL, Finocchi C, Gandolfo C. Migraine with aura and right-to-left shunt on transcranial doppler:a case-control study[J]. Cerebrovasc Dis, 1998, 8:327-330.
[18] Schwedt TJ, Demaerschalk BM, Dodick DW. Patent foramen ovale and migraine:a quantitative systematic review[J]. Cephalalgia, 2008, 28:531-540.
[19] Lip PZ, Lip GY. Patent foramen ovale and migraine attacks:a systematic review[J]. Am J Med, 2014, 127:411-420.
[20] Takagi H, Umemoto T; ALICE (All-Literature Investigation of Cardiovascular Evidence) Group. A meta-analysis of case-control studies of the association of migraine and patent foramen ovale[J]. J Cardiol, 2016, 67:493-503.
[21] Wang SB, Liu KD, Yang Y, Li YJ, Hu MY, Lin P, Guo R, Tian Q, You Y, Cui YH, Zhang GL, Dong Z, Gao YS, Xing YQ. Prevalence and extent of right-to-left shunt on contrast-enhanced transcranial doppler in Chinese patients with migraine in a multicentre case-control study[J]. Cephalalgia, 2018, 38:690-696.
[22] Tian DC, Wang H, Chen W, Tian X, Zhang LJ, Hui X, Wang XJ. Meta-analysis of relationship between patent foramen ovale and migraine[J]. Shen Jing Sun Shang Yu Gong Neng Chong Jian, 2019, 14:236-240.[田大臣,王浩,陈旺,田茜,张利军,惠鑫,王贤军.卵圆孔未闭与偏 头痛发病相关性的Meta分析[J].神经损伤与功能重建, 2019, 14:236-240.]
[23] Kumar P, Kijima Y, West BH, Tobis JM. The connection between patent foramen ovale and migraine[J]. Neuroimaging Clin N Am, 2019, 29:261-270.
[24] Kahya Eren N, Bülbül NG, Yakar Tülüce S, Nazl? C, Beckmann Y. To be or not to be patent:the relationship between migraine and patent foramen ovale[J]. Headache, 2015, 55:934-942.
[25] Naqvi TZ, Rafie R, Daneshvar S. Original investigations:potential faces of patent foramen ovale (PFO PFO)[J]. Echocardiography, 2010, 27:897-907.
[26] Sharma A, Gheewala N, Silver P. Role of patent foramen ovale in migraine etiology and treatment:a review[J]. Echocardiography, 2011, 28:913-917.
[27] Bongsebandhu-Phubhakdi S, Phisonkulkasem T, Srikiatkhachorn A. Nociceptin/orphanin FQ modulates cortical activity and trigeminal nociception[J]. Headache, 2011, 51:1245-1253.
[28] Ning M, Navaratna D, Demirjian Z, Inglessis-Azuaje I, McMullin D, Dec GW. How the heart whispers to the brain:serotonin as neurovascular mediator in patent foramen ovale related stroke[J]. Stroke, 2011, 42.
[29] Deng W, McMullin D, Wickham T, Feeney K, Inglessis I, Palacios I, Buonanno F, Lo EH, Ning M. Abstract TP426:PFO closure reduces plasma levels of serotonin in long term follow up of stroke patients[J]. Stroke, 2016, 47(Suppl_1):ATP426.
[30] Nozari A, Dilekoz E, Sukhotinsky I, Stein T, Eikermann-Haerter K, Liu C, Wang Y, Frosch MP, Waeber C, Ayata C, Moskowitz MA. Microemboli may link spreading depression, migraine aura, and patent foramen ovale[J]. Ann Neurol, 2010, 67:221-229.
[31] Khasiyev F, Arsava EM, Topcuoglu MA. Cerebral vasomotor reactivity in migraine:effect of patent foramen ovale and aerogenic microembolism[J]. Neurol Res, 2020, 42:795-804.
[32] Altamura C, Paolucci M, Brunelli N, Cascio Rizzo A, Cecchi G, Assenza F, Silvestrini M, Vernieri F. Right-to-left shunts and hormonal therapy influence cerebral vasomotor reactivity in patients with migraine with aura[J]. PLoS One, 2019, 14:e0220637.
[33] Liu K, Wang BZ, Hao Y, Song S, Pan M. The correlation between migraine and patent foramen ovale[J]. Front Neurol, 2020, 11:543485.
[34] Wilmshurst PT, Pearson MJ, Nightingale S, Walsh KP, Morrison WL. Inheritance of persistent foramen ovale and atrial septal defects and the relation to familial migraine with aura[J]. Heart, 2004, 90:1315-1320.
[35] Shi YJ, Lv J, Han XT, Luo GG. Migraine and percutaneous patent foramen ovale closure:a systematic review and meta-analysis[J]. BMC Cardiovasc Disord, 2017, 17:203.
[36] Dowson A, Mullen MJ, Peatfield R, Muir K, Khan AA, Wells C, Lipscombe SL, Rees T, De Giovanni JV, Morrison WL, Hildick-Smith D, Elrington G, Hillis WS, Malik IS, Rickards A. Migraine intervention with STARFlex technology (MIST) trial:a prospective, multicenter, double-blind, sham-controlled trial to evaluate the effectiveness of patent foramen ovale closure with STARFlex septal repair implant to resolve refractory migraine headache[J]. Circulation, 2008, 117:1397-1404.
[37] Mattle HP, Evers S, Hildick-Smith D, Becker WJ, Baumgartner H, Chataway J, Gawel M, Göbel H, Heinze A, Horlick E, Malik I, Ray S, Zermansky A, Findling O, Windecker S, Meier B. Percutaneous closure of patent foramen ovale in migraine with aura, a randomized controlled trial[J]. Eur Heart J, 2016, 37:2029-2036.
[38] Tobis JM, Charles A, Silberstein SD, Sorensen S, Maini B, Horwitz PA, Gurley JC. Percutaneous closure of patent foramen ovale in patients with migraine:the PREMIUM Trial[J]. J Am Coll Cardiol, 2017, 70:2766-2774.
[39] Elbadawi A, Barssoum K, Abuzaid AS, Rezq A, Biniwale N, Alotaki E, Mohamed AH, Vuyyala S, Ogunbayo GO, Saad M. Meta-analysis of randomized trials on percutaneous patent foramen ovale closure for prevention of migraine[J]. Acta Cardiol, 2019, 74:124-129.
[40] Kheiri B, Abdalla A, Osman M, Ahmed S, Hassan M, Bachuwa G, Bhatt DL. Percutaneous closure of patent foramen ovale in migraine:a meta-analysis of randomized clinical trials[J]. JACC Cardiovasc Interv, 2018, 11:816-818.
[41] He Q, Zhang Y, Wang F, Li C, Guo R, Li X, Luan B, Zhao H, Meng L, Chen H, Meng L. Impact of right-to-left shunt and transcatheter closure on the clinical features of migraine[J]. Int J Neurosci, 2020, 130:270-275.
[42] He YD, Yan XL, Qin C, Zhang P, Guo ZN, Yang Y. Transcatheter patent foramen ovale closure is effective in alleviating migraine in a 5-year follow-up[J]. Front Neurol, 2019, 10:1224.
[43] Cardiovascular Physicians Branch, Chinese Physicians Association. Recommendations from Chinese experts on management of patients with patent foramen ovale[J]. Xin Zang Za Zhi, 2015, 27:373-379.[中国医师协会心血管内科医师分会.卵圆孔未闭处理策略中国专家建议[J]. 心脏杂志, 2015, 27:373-379.]